Dendreon Corporation Announces Management Promotions.Business Editors/Health & Medical Writers SEATTLE--(BUSINESS WIRE)--Dec. 30, 2002 Dendreon Corporation (Nasdaq:DNDN) today announced the promotions of Elizabeth C. Smith to Vice President, Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Smith, former director of regulatory affairs, joined Dendreon in 1999. Prior to that time, Smith worked at Genentech, Inc. as regulatory affairs manager in manufacturing and facilities and at Immunex Corporation as a senior regulatory affairs associate. Cardwell, former director of quality assurance and quality control, joined Dendreon in 1998. Prior to that time, Cardwell worked for Genetic Systems/Sanofi in various positions including manager of biologicals manufacturing and quality and quality services manager. Cardwell is active in the Seattle quality and regulatory community as president-elect of the Organization for Clinical and Regulatory Affairs (ORCA Orca - Vrije Universiteit, Amsterdam, 1986. Similar to Modula-2, but with support for distributed programming using shared data objects, like Linda. A 'graph' data type removes the need for pointers. Version for the Amoeba OS, comes with Amoeba. ) and chairperson of ORCA's committee on biotechnology. "Elizabeth Smith Elizabeth Smith is a Scottish Conservative Party politician, and Member of the Scottish Parliament for Mid Scotland and Fife. • • and Lizabeth Cardwell have made key contributions to the development of our lead product candidate, Provenge(TM), a therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. ," said David Urdal, Ph.D., president and chief scientific officer. "Their leadership will continue to serve Dendreon well as we work to bring Provenge to market and advance our other product candidates." Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. Dendreon currently has multiple therapeutic vaccines in clinical trials. Dendreon's product pipeline also includes monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and a pathway to small molecules. Dendreon has established important alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. For more information, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Factors that may cause such a difference include reliance on key employees, especially senior management, risks related to Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the results of a clinical trial will not support applying for or approval of a biologics license by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , the uncertainty of Dendreon's future access to capital, the risk that Dendreon may not secure or maintain relationships with collaborators, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion